Grünenthal Group Company Presentation
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Grünenthal Group Company Presentation
Disclaimer
This presentation has been prepared solely for the purpose of giving a short introduction
about the Grünenthal Group. The presentation is a brief summary about the company and
the information contained therein cannot be assumed as being complete. Thus you
should not place undue reliance on the information contained in this summary:
No representations or warranty are made as to the accuracy or completeness of any
information, statements, estimates or projections given within this presentation: nothing
contained herein is, or should be, relied on, as a promise or representation as to the
future performance of the companies belonging to the Grünenthal Group. Neither
Grünenthal nor any member of the Grünenthal Group, nor its respective directors,
officers, employees, representatives or agents shall have any obligation to provide
additional information or to correct or update any information set forth in this summary.
grunenthal.com Grünenthal Company Presentation as of 01/2018 2
About us
Our Ambition
We are an entrepreneurial,
science-based pharmaceutical company,
specialized in pain, gout & inflammation.
Our ambition is to deliver four to five new products
to patients in diseases with high unmet medical need
by 2022 and become a € 2 billion company.
We will be turbo charging our delivery from, within
and with collaborating with external partners.
Be a Great Place to Work®!
grunenthal.com 4
Delivering products to patients in diseases with high
unmet medical need
We are committed to listening to patients and learning from them
to bring a real difference in their lives
We support patients’ empowerment so they can expand their knowledge
regarding management of their diseases
We are committed to continued research of innovative products that
directly address the needs of patients suffering from pain and diseases with
high medical need
We strive to support patients and health authorities to develop and implement
policies addressing health issues and improving quality of life
grunenthal.com 5
Grünenthal’s Corporate Executive Board Gabriel Baertschi Sascha Becker Mark Fladrich Dr. Klaus-Dieter Langner Chief Executive Officer (CEO) Chief Financial Officer (CFO) Chief Commercial Officer (CCO) Chief Scientific Officer (CSO) Grünenthal Group Grünenthal Group Grünenthal Group Grünenthal Group grunenthal.com 6
About us
Founded Shareholders Executive Board Headquarters R&D units
in 1946 100% Wirtz Family CEO: Aachen,
Germany
Gabriel Baertschi (Aachen)
Fully integrated Germany
Latin America
CFO:
R&D-based company (Santiago de Chile)
Sascha Becker
USA
CCO:
Mark Fladrich (Morristown, NJ)
CSO:
Dr. Klaus-D. Langner R&D hubs
USA
(Boston, MA)
The Netherlands
(Leiden)
grunenthal.com 7About us
Revenues 2016 155 countries Focussed Targeted Targeted
€1.4 bn in which our products Regions Audience Audience
are available
Equity Ratio 2016 32 countries Europe Europe Latin America*
59% in which we have pain specialists, pain specialists,
affiliates rheumatologists, orthopaedics,
Latin America orthopaedics, neurologists,
Number of neurologists, oncologists, psychiatrists,
employees North America rehabilitators, gynaecologists, ENT**,
~5,500 worldwide (co-operation) anaesthesiologists, surgeons, oncologists,
(~650 in R&D) surgeons, general paediatrics, internal
practitioners medicine & general
Field Sales Force
practitioners
~1,800 worldwide
* Besides the shown targeted audience, there are further country-specific particularities depending on the local portfolio
** Ear Nose & Throat specialists
grunenthal.com 8Reaching patients across the world with our expertise
Presence in various
markets (155 countries) Revenues 2016:
€1.4 bn
2nd place in Europe,
PALEXIA ®–
6th place worldwide1 Highlight:
in the area of Grünenthal’s Tapentadol,
centrally acting analgesics first innovative molecule in
the centrally acting analgesic class
approved in more than 25 years
1 Source: IMS HEALTH 2016
grunenthal.com 9Europe and Latin America: Focused search fields
preferably covered by our current target audience
Europe Latin America
Pain Pain
Inflammation Women's health
Movement/Bone disorders Central Nervous System
Perioperative care Cancer treatment and care
Neurology
Cancer supportive care
Focused & specialty drugs
Hospital based business
grunenthal.com 10R&D: Pain and focused search fields preferably covered
by our current target audience
R&D
Pain
Inflammation (niches)
Perioperative Care
Cancer supportive care
Focused & specialty drugs
grunenthal.com 11Our Business
Grünenthal in a snapshot
Committed to Expand our R&D and Strong partnership
delivering true benefits Licensing, Mergers & is the key of
to patients Acquisitions in pain and our success
beyond
and in line with our
target audience
grunenthal.com 13Our strategic objectives
Maximize pipeline and Grow Raise Mitigate pipeline risk
existing market profit contribution Latin American by creating broader
portfolio; strengthen allowing for value contribution to portfolio with smaller,
our position in pain, sustainable R&D the same level more focused projects
gout & inflammation cycle – doubling as Europe in areas with high
and focused R&D investment unmet medical need
indications covered
by our target audience
grunenthal.com 14Our successful partnering model builds on…
An integrated BD&L1 approach, from target identification to project implementation
Broad market screening and scouting for new opportunities through
dedicated Growth Task Forces
State of the art deal making, applying classical as well as
innovative deal structuring
Professional deal implementation and cooperation through
a dedicated Strategic Alliance Management function
1 BD&L: Business Development and Licensing
grunenthal.com 15Utilization of our existing field sales force supports our
successful partnering model – Europe
~ 700 sales representatives
~ 1.000.000 of calls
~ 190.000 physicians visited
Optimized coverage of main pain related targets
grunenthal.com 16Utilization of our existing field sales force supports our
successful partnering model – Latin America
~ 795 sales representatives
~ 1.300.000 of calls*
~ 120.000 physicians visited
Optimized coverage of main pain, women's health and central nervous system
related targets
grunenthal.com * Excluding Venezuela 17Global presence
Pain leadership in established markets and adaptation to emerging markets in Latin America
Objectives
Preferred partner for our target groups in pain and beyond
Among Top 10 in the pharmaceutical industry in Latin America
Benefit from US market potential via strong partners
Facts
Affiliates in 32 countries
Production sites in six countries on two continents
International business: 88% of revenues
Products available in 155 countries
grunenthal.com 18Market presence
Aachen, DE, Headquarters
Area of Mitlödi, CH
Morristown, USA
Milan, IT
Miami, USA
Panama, PA
Quito, EC
Itajaí1, BR
R&D - Unit
Production Santiago de Chile, CL
Service Office
Regional Office Grünenthal affiliates Partner countries Other countries
1Approval of the plant by the authorities in 2017
grunenthal.com 19Grünenthal in Europe
Strong coverage of the home market
Revenues 2016
€ 848 mn with a focused portfolio in a stable macro economy and a culture
where WHO step II and III analgesics are fully accepted (also outside cancer pain)
Growth rate
Countries
2016 vs. 2015
Italy +57%
Nordics +34%
France +26%
Spain +24%
Ireland +24%
Germany +16%
Switzerland +15%
Netherlands +5%
Portugal +1%
Austria +0%
Belgium -2%
Grünenthal affiliates
United
Partner countries -28%
Kingdom
Other countries Gesamt +21%
grunenthal.com 20Grünenthal in Latin America
Out of pocket driven markets balance payor driven markets in EU
Revenues 2016
€ 353 mn with broader portfolio in a sometimes uncertain but
dynamic market environment where strong opioids are very restricted
Growth rate
Countries
2016 vs. 2015
Bolivia +17%
Brazil +15%
Columbia +13%
Mexico +9%
Chile +7%
Ecuador +5%
Peru +1%
Grünenthal affiliates CAM1 -10%
Partner countries Total2 +7%
Other countries 1 CAM = Central America & Caribbean
2 (w/o) Venezuela
grunenthal.com 21Percentage distribution of revenues 2016
Europe, Latin America and North America
Europe Latin America North America
Others
13%
Pain Others Pain Pain
87% 32% 36% 100%
Anti-
infective
5%
Urology Women‘s
1% CNS health
12% 14%
grunenthal.com 22Main Marketed Products
Market Launch Net Revenues Growth (FX adjusted)
(2016, € mn) (2016, ±%)
2007 229 +26
coop.1 20142 207 >+100
2010 186 +25
1977 111 -1
2001
95 -7
2007
2003 83 -1
2010 73 -9
IR/ER USA: 2009 37 +22
1 MSD coop. covers the products Arcoxia® , Exinef® , Fosavance® and since 2016 Esmeron® & Bridion® and additional local products in Latin America
2 Distribution take over
grunenthal.com 23Grünenthal Main Marketed Products
IR/ER
coop.1
1970 1980 1990 2000 2002 2004 2006 2008 2010 2012 2014 2016 2020
1 MSD coop. covers the products Arcoxia® , Exinef® , Fosavance® and since 2016 Esmeron® & Bridion® and additional local products in Latin America
grunenthal.com 24Product Performance
Clear focus on global brands in pain market
Revenues by products 20161 (€ mn) FX (adjusted) growth 2016 vs. 2015
2%
other revenues +50%
13%
16% Palexia®
other local brands 27 +26%
106 186 3%
Nucynta®
37 +25%
17%
local brands 236
Latin America +23%
16%
1.390 229 Versatis® LatAm Local
5% +13%
TRF / INTAC® 73 Brands
8%
Tramal® -1%
111 6%
207 -1%
Zaldiar® 2 Increased
15% 83
MSD Coop.3 95 7% generic
Transtec®/Norspan® -7% pressure
1 All values in mn € and exchange rate of the respective business year
2 Incl. Ixprim ®
3 MSD coop. covers Arcoxia® , Exinef® , Fosavance® and since 2016 Esmeron® & -9%
Bridion® and additional local products in Latin America
grunenthal.comCorporate Performance
Striving for sustainable growth
Revenue development Revenue split by SBU
(€ mn, 2005 – 2016) (%, 2015 – 2016)
1.390
7%
9%
1.212
CAGR +5% 2015
Zaldiar
Zaldiar 1.154 27% 58%
generics
Generika
SBU Europe
159
SBU Latin America
973* BU North Amerika
947* 9
910* 901 Others
864 881 92
846 97 6%
813 8%
777
25% 2016
61%
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
thereof divestments thereof acquisitions
* Annual net revenues including divestments
CAGR = Compound Annual Growth Rate (S)BU = (Strategic Business Unit)
grunenthal.com 26Grünenthal’s strong position in Europe in the segment of Centrally Acting Analgesics European Revenues & Market Shares 2016 and Growth vs. 2015 Rank Company Revenues (€ mn) Market Shares (%) Growth vs. PY (%) 1 Mundipharma (US) 651 20,3% -1,8% 2 Grünenthal (DE) 403 12,6% +6,9% 3 Stada (DE) 273 8,5% +4,6% 4 Novartis (CH) 198 6,2% +5,6% 5 Teva (IL) 184 5,7% ±0,0% 6 Johnson & Johnson (US) 152 4,7% -9,1% 7 Kyowa Hakko Kirin (JP) 137 4,3% +10,7% 8 Sanofi (FR) 119 3,7% -7,2% 9 Takeda (JP) 98 3,1% +9,8% 10 Mylan (US) 75 2,4% +13,7% Source: IMS HEALTH 2016 grunenthal.com 27
Grünenthal’s strong position in Latin America
in the segment of Centrally Acting Analgesics
Latin America Revenues & Market Shares 2016 and Growth vs. 2015
Rank Company Revenues (€ mn) Market Shares (%) Growth vs. PY (%)
1 Grünenthal (DE) 92,0 31,5% +59,1%
2 Johnson & Johnson (US) 29,8 10,2% -2,7%
3 Eurofarma (BR) 17,7 6,0% +39,1%
4 Mundipharma (US) 13,0 4,4% +18,5%
5 Cristalia (BR) 12,3 4,2% +23,4%
6 Finadiet (AR) 10,5 3,6% +48,2%
7 Valmorca (VE) 8,6 2,9% +899,7%
8 Teva (IL) 7,9 2,7% -37,3%
9 EMS (BR) 7,8 2,7% +23,2%
10 Ache Labs (BR) 6,6 2,3% +44,8%
Source: IMS HEALTH 2016
grunenthal.com 28R&D and Pipeline
Grünenthal Innovation: Some key numbers
We have worked in the pain area for more than 40 years so we have
>40 the experience and dedication to develop new medicines for pain patients
Our budget for Grünenthal Innovation – the core area of R&D –
~230 is about € 230 mn, to invest into new projects and our infrastructure
About 650 colleagues work across all aspects of R&D which are required to take
~650 a compound from idea to a medicine
We have filed around 330 patent applications over the last ten years
330 protecting our novel ideas
grunenthal.com 30A strong R&D output
Grünenthal products benefit patients worldwide
Worldwide revenues of selected discovered and all developed Grünenthal products
MNF1 sales in € LC2 bn
Without INTAC® revenues 2,27
2,05
1,84
1,66 1,70
WW3 total
ROW 4
North America
Latin America
Europe
2012 2013 2014 2015 2016
1 MNF: Manufacturer Selling Price 2 LC: Local Currency 3 WW: worldwide 4 ROW: Rest of World
Source: IMS HEALTH 2016
grunenthal.com 31Grünenthal commits to innovation
We have the means and the attitude
The Means The Attitude
Fully integrated R&D organization Meaningful contribution to healthcare is our
motivation
Extensive expertise and capabilities
We know that there is no progress without
Sustainable investment in core R&D: trial and error
on average 15% of revenues every year
(which equals 19% total R&D) We strongly believe that the markets will
reward those who make a real difference
Financially strong with high equity ratio
grunenthal.com 32Contact us
Contact us Štěpán Kráčala Head Global Corporate Communications Grünenthal GmbH 52099 Aachen Email: stepan.kracala@grunenthal.com Telephone: +49 241 569 1335 grunenthal.com 34
You can also read
